Coinfection
ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 01 October 2013 00:00
- Written by Liz Highleyman
Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage in HIV positive people with hepatitis B or C coinfection, contributing to a high mortality rate that has changed little in recent years, according to a report at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.
Tenofovir Is Highly Effective for HIV/HBV Coinfection, Meta-analysis Shows
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 27 August 2013 00:00
- Written by Liz Highleyman
Tenofovir, which has potent activity against both HIV and hepatitis B virus (HBV), is the most effective hepatitis B treatment for HIV/HBV coinfected people, according to a 23-study meta-analysis described in the July 10, 2013, issue of the open-access journal PLoS One. Combining it with emtricitabine did not improve hepatitis B response.
CROI 2013: Retrovirus Conference Starts Sunday in Atlanta
- Details
- Category: HIV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) kicks off Sunday, March 3, at the Georgia World Congress Center in Atlanta. HIVandHepatitis.com will be on site next week to bring you breaking news coverage on HIV and hepatitis C.
Look for reports from the HIVandHepatitis.com team and our content partners at NAM/Aidsmap.com starting Monday. Sign up for our email newsletter to get the latest headlines and follow us on Twitter @HIVandHepatitis.
IAS 2013: People with HBV or HCV Coinfection May Not Respond as Well to HIV Treatment
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
HIV positive people with hepatitis B or C coinfection in Asia had lower CD4 T-cell counts, saw smaller CD4 cell gains after starting antiretroviral therapy, and had a higher risk of death, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
Tenofovir plus Emtricitabine or Lamivudine Does Not Always Suppress Hepatitis B in HIV/HBV Coinfected
- Details
- Category: HIV/HBV Coinfection
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people with high hepatitis B virus (HBV) levels and those who are HBeAg positive are at greater risk of not achieving HBV suppression after a year on tenofovir plus emtricitabine or lamivudine, but most did so eventually, researchers reported in the February 21, 2013, advance online edition of AIDS.
CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection
- Details
- Category: HBV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
Use of antiretroviral therapy (ART) that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that HIV positive people will become infected with HBV -- in effect acting as HBV PrEP -- according to a study presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 04 December 2012 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week announced an update to the label information for adefovir dipivoxil (Hepsera), adding the 4-in-1 antiretroviral combination pill Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) to the list of other products that should not be co-administered with adefovir.
Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Monday, 04 March 2013 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.
Conference highlights include HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions and complications, treatment as prevention and PrEP, new treatments for hepatitis C, and HIV/HBV and HIV/HCV coinfection.
HIVandHepatitis.com CROI 2013 conference section
3/4/13
Coverage of the 2012 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
HIVandHepatitis.com AASLD 2012 conference section
11/13/12